Quizartinib is another second-generation inhibitor that solely targets FLT3-ITD that has also been compared to salvage chemotherapy in relapse/refractory FLT3-ITD AML in the phase 3 QuANTUM-R study. This evidence concerns the gene FLT3 and acute myeloid leukemia.